Vyndaqel Capsules Special Investigation (ATTR-CM)

NCT04108091

Last updated date
Study Location
Pfizer
Tokyo, , , Japan
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transthyretin (TTR) Amyloid Cardiomyopathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients administered Vyndaqel for the treatment of ATTR-CM

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- N/A

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Transthyretin (TTR) Amyloid CardiomyopathySafety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy NCT01994889
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Phoenix, Arizona
  5. Phoenix, Arizona
  6. Scottsdale, Arizona
  7. La Jolla, California
  8. La Jolla, California
  9. La Jolla, California
  10. La Jolla, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. San Francisco, California
  15. Stanford, California
  16. Deerfield Beach, Florida
  17. Miami, Florida
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Oak Lawn, Illinois
  21. New Orleans, Louisiana
  22. Baltimore, Maryland
  23. Baltimore, Maryland
  24. Baltimore, Maryland
  25. Boston, Massachusetts
  26. Boston, Massachusetts
  27. Boston, Massachusetts
  28. Boston, Massachusetts
  29. Ann Arbor, Michigan
  30. Rochester, Minnesota
  31. Rochester, Minnesota
  32. Newark, New Jersey
  33. New York, New York
  34. New York, New York
  35. New York, New York
  36. New York, New York
  37. New York, New York
  38. New York, New York
  39. Durham, North Carolina
  40. Cleveland, Ohio
  41. Portland, Oregon
  42. Portland, Oregon
  43. Portland, Oregon
  44. Philadelphia, Pennsylvania
  45. Nashville, Tennessee
  46. Houston, Texas
  47. Salt Lake City, Utah
  48. Richmond, Virginia
  49. Richmond, Virginia
  50. Seattle, Washington
  51. Leuven,
  52. Rio de Janeiro, RJ
  53. Calgary, Alberta
  54. Toronto, Ontario
  55. Brno,
  56. Brno,
  57. Praha 2,
  58. Praha 2,
  59. Praha 4,
  60. Praha 4,
  61. Clamart,
  62. Creteil,
  63. Heidelberg,
  64. Muenster,
  65. Bologna,
  66. Brescia,
  67. Firenze,
  68. Pavia,
  69. Kurume-shi, Fukuoka
  70. Kumamoto-city, Kumamoto
  71. Nagano,
  72. Groningen,
  73. Majadahonda, Madrid
  74. El Palmar, Murcia
  75. A Coruna,
  76. Skelleftea,
  77. Uppsala,
  78. London,
  79. London,
  80. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Transthyretin (TTR) Amyloid CardiomyopathyLong-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy NCT02791230
  1. Baltimore, Maryland
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Beverly Hills, California
  6. Beverly Hills, California
  7. La Jolla, California
  8. La Jolla, California
  9. Los Angeles, California
  10. San Diego, California
  11. San Francisco, California
  12. San Francisco, California
  13. San Francisco, California
  14. Stanford, California
  15. Stanford, California
  16. Deerfield Beach, Florida
  17. Miami, Florida
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Oak Lawn, Illinois
  22. Baltimore, Maryland
  23. Boston, Massachusetts
  24. Boston, Massachusetts
  25. Boston, Massachusetts
  26. Ann Arbor, Michigan
  27. Ann Arbor, Michigan
  28. Rochester, Minnesota
  29. Rochester, Minnesota
  30. Newark, New Jersey
  31. New York, New York
  32. New York, New York
  33. Durham, North Carolina
  34. Cleveland, Ohio
  35. Portland, Oregon
  36. Portland, Oregon
  37. Portland, Oregon
  38. Philadelphia, Pennsylvania
  39. Nashville, Tennessee
  40. Salt Lake City, Utah
  41. Salt Lake City, Utah
  42. Salt Lake City, Utah
  43. Ciudad Autónoma de Buenos Aires,
  44. Westmead, New South Wales
  45. Woolloongabba, Queensland
  46. Box Hill, Victoria
  47. Leuven,
  48. Rio de Janeiro, RJ
  49. Calgary, Alberta
  50. Vancouver, British Columbia
  51. Vancouver, British Columbia
  52. Toronto, Ontario
  53. Toronto, Ontario
  54. Montreal, Quebec
  55. Montreal, Quebec
  56. Brno,
  57. Praha 2,
  58. Praha 4,
  59. Marseille, Provence
  60. Creteil,
  61. Marseille,
  62. Paris,
  63. Rennes,
  64. Rennes,
  65. Toulouse,
  66. Heidelberg,
  67. Münster,
  68. Hong Kong,
  69. Hong Kong,
  70. Bologna,
  71. Firenze,
  72. Pavia,
  73. Kurume-shi, Fukuoka
  74. Kumamoto-city, Kumamoto
  75. Nagano,
  76. Groningen,
  77. Majadahonda, Madrid
  78. A Coruña,
  79. Skellefteå,
  80. Uppsala,
  81. Taipei,
  82. Taipei,
  83. Taipei,
  84. Taipei,
  85. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Transthyretin (TTR) Amyloid CardiomyopathyVyndaqel Capsules Special Investigation (ATTR-CM) NCT04108091
  1. Tokyo,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Vyndaqel Capsules Special Investigation (ATTR-CM)
Official Title DRUG USE INVESTIGATION OF TAFAMIDIS MEGLUMINE FOR TTR-CM (POST MARKETING COMMITMENT PLAN)
Brief Summary Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan.
Detailed Description To comprehend information on the long-term safety (e.g., onset status of adverse reactions), etc. of patients who are treated with Vyndaqel for the treatment of transthyretin amyloid cardiomyopathy.
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients who are administered with this drug for the treatment of ATTR-CM
Condition Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention Drug: Treatment for TTR amyloidosis
The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
Other Name: Vyndaqel
Study Groups/Cohorts Treatment for TTR amyloidosis
Transthyretin amyloid cardiomyopathy (wild-type or variants) patients administered Vyndaqel
Intervention: Drug: Treatment for TTR amyloidosis
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: September 26, 2019)
360
Original Estimated Enrollment Same as current
Estimated Study Completion Date April 10, 2024
Estimated Primary Completion Date April 10, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients administered Vyndaqel for the treatment of ATTR-CM

Exclusion Criteria:

  • N/A
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries Japan
Removed Location Countries  
 
Administrative Information
NCT Number NCT04108091
Other Study ID Numbers B3461064
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2019